I have to agree.
What stands out for me is pain management revenue on page 13. Just under $1.945m this half compared to 1.734m last half. I thought last years sales were covid suppressed. Thought it should have taken off. 12% growth is not really indicating that their strategy in France/Europe is working. There must be other countries mixed in here, but need this doubled!!
On current run rate they’ll need cash again in mid 2024. Especially if the US trial kicks off. They say on page 6 complete US funding plan, wasn’t that the cap raise?
On a positive note is increase pricing in Australia, but you’d really want that across all markets in the current environment.
Respiratory was a solid result, but care less for that product. The green whistle is what we need to grow!!
I have to agree.What stands out for me is pain management...
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
-0.035(7.95%) |
Mkt cap ! $34.95M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.0¢ | 40.5¢ | $82.07K | 192.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6002 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 3044 | 1 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
40.5¢ |
Change
-0.035 ( 3.69 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 43.5¢ | 40.5¢ | 43358 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| MVP (ASX) Chart |